October 3rd, 2026
Description
Ocular oncology continues to face several persistent practice gaps that limit clinicians’ ability to deliver timely, evidence‑based care. Many providers struggle with early and accurate diagnosis due to inconsistent use of advanced imaging modalities and limited familiarity with emerging AI‑driven diagnostic tools. There are also notable gaps in understanding genetic and molecular risk stratification, including how gene expression profiling and germline mutations such as BAP1 should guide surveillance and treatment decisions. As new therapies rapidly enter the field, clinicians often lack clarity on how to integrate novel systemic, targeted, and local treatments into existing care pathways, particularly for uveal melanoma and retinoblastoma. Management of treatment‑related toxicities—especially radiation‑induced complications—remains variable, reflecting a need for updated strategies and greater comfort with evolving mitigation techniques. Multidisciplinary coordination is another challenge, with inconsistent referral pathways and limited collaboration across ocular oncology, medical oncology, radiation oncology, pathology, and genetics. Additionally, disparities in access to specialized care persist, particularly for patients with rare tumors or high‑burden conditions. Finally, clinicians frequently report limited familiarity with current clinical trials, translational research developments, and emerging biomarkers, underscoring the need for improved research literacy and navigation of trial opportunities.
Dates and Times
Start: 10/3/2026 8:00 AM
End: 10/3/2026 4:30 PM
Objectives
1. Apply advanced imaging techniques and molecular profiling results to improve diagnostic accuracy and staging of ocular tumors.
2. Select appropriate evidence‑based treatment strategies for uveal melanoma, retinoblastoma, and ocular surface tumors, including emerging systemic and targeted therapies.
3. Identify and manage treatment‑related toxicities such as radiation‑induced complications and adverse effects of systemic therapies.
4. Implement effective multidisciplinary care pathways that enhance coordination among ophthalmology, oncology, radiation oncology, pathology, and genetics teams.
5. Incorporate current clinical trial options, biomarkers, and translational research findings into patient counseling and treatment planning.
Pricing
| Tier | Price |
|---|---|
| Resident | $50.00 |
| Physician | $150.00 |
Location
Ohio State Eye and Ear Institute
915 Olentangy River Rd.
Columbus, OH 43212
Accreditation Statement
The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The Ohio State University designates this live activity for a maximum of 9.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.